Additionally, emerging fourth-generation inhibitors such as TPX-0131 and NVL-655 are being evaluated for their efficacy against ALK-positive advanced/metastatic NSCLC and other solid tumors [37,38,39]. Here, ALK is linked to non-small cell lung carcinoma.